# Latus Bio reports MSH3 gene therapy LTS-201 lowers its target in primates and mice

- Published: 2026-11-08 07:38 UTC
- Section: Life & Health › Biotechnology
- Tags: Latus Bio, LTS-201, Huntington's disease gene therapy, MSH3, somatic instability, AAV-DB-3, artificial microRNA, CAG repeat, Nature Communications
- URL: https://realtech.media/news/rt-aa35ce21c21456c74696804f_latus_bio_reports/

**Latus Bio published preclinical data in Nature Communications on LTS-201, an AAV therapy that lowers MSH3 to curb DNA repeat expansion in Huntington's disease.**

![Latus Bio reports MSH3 gene therapy LTS-201 lowers its target in primates and mice](https://realtech.media/media/2026/11/7739b405c09df826.jpg)
*Maggie Bartlett, NHGRI, Wikimedia Commons, Public domain*

Latus Bio Inc. (Philadelphia, PA) has published a peer-reviewed study in Nature Communications supporting a gene therapy approach to Huntington's disease that targets the DNA repair protein MSH3, according to mychesco.com [1]. The work combines human disease progression data, computational modeling and animal experiments. It tests whether reducing MSH3 could delay symptoms and preserve neurological function [1].

The experimental treatment, LTS-201, remains at the preclinical stage. The study is the basis for the company's strategy, not evidence of effect in patients [1].

## Mechanism and delivery

The strategy targets somatic instability, a process in which inherited DNA repeat sequences expand within cells over time. This expansion is increasingly implicated in the onset and progression of the disease [1]. Unlike approaches focused mainly on the huntingtin protein, the Latus Bio strategy targets a DNA repair mechanism that contributes to continued expansion of the mutation in vulnerable neurons [1].

LTS-201 uses an engineered adeno-associated virus (AAV) to deliver an artificial microRNA designed to reduce MSH3 expression in specific brain cells. The vector, AAV-DB-3, is engineered to target medium spiny neurons in the striatum and projection neurons in the cerebral cortex [1].

## Animal data and model

In nonhuman primates, LTS-201 reduced MSH3 messenger RNA by 48% to 94%, depending on the dose, in more than 90% of medium spiny neurons examined. In a mouse model of Huntington's disease, the authors observed dose-dependent reductions in somatic instability in the striatum [1].

The authors also built a computational model from human natural history data and measurements of somatic expansion in human neurons. Its simulations suggested that substantial, sustained MSH3 reductions could delay motor symptom onset and slow clinical deterioration by years. Earlier intervention could produce benefits measured in decades. Simulated changes in the rate of decline on the cUHDRS scale ranged from about 50% to more than 120% relative to natural history [1].

The model also predicted that deeper suppression in a smaller share of vulnerable neurons could be more effective than weaker suppression across a larger share [1]. These estimates are computational predictions, not demonstrated clinical outcomes [1].

Jang-Ho J. Cha, chief science and medical officer of Latus Bio and a co-corresponding author, said the work establishes a translational framework linking MSH3 lowering to reduced somatic instability [1]. The researchers note that the modeling framework could also apply to other repeat-expansion disorders, including X-linked dystonia-parkinsonism and myotonic dystrophy type 1 [1].

## Sources

1. [mychesco.com](https://www.mychesco.com/a/news/regional/latus-bio-study-advances-gene-therapy-strategy-for-huntingtons)

---

Source: RealTech, realtech.media — https://realtech.media/news/rt-aa35ce21c21456c74696804f_latus_bio_reports/